Elzagheid A, Kuopio T, Ilmen M, Collan Y
Department of Pathology, University of Turku, Finland.
Histopathology. 2002 Aug;41(2):127-33. doi: 10.1046/j.1365-2559.2002.01448.x.
We tried to improve the evaluation of E-cadherin immunostaining in paraffin sections, to distinguish the less aggressive variants of ductal infiltrating breast cancer from other variants.
The method graded the membrane staining and estimated the fraction of area of cancer tissue stained at the respective staining grade, resulting in an immunohistochemical staining index. At the cut-point 0.35 the index divided all 157 patients (P=0.0188), and 57 node-positive patients (P= 0.0006) into two groups of different survival. In multivariate analysis (all patients) E-cadherin immunoscore was inferior to mitotic index (SMI) (P=0.0002), but still significant (P=0.0031). Among node-positive patients E-cadherin was even more powerful and superior (P=0.0001) to the still significant SMI (P=0.0023), and E-cadherin immunostaining and the mitotic activity (SMI) combined did not need the support of other prognosticators in the Cox model.
The study suggests that E-cadherin immunostaining can be used efficiently in finding patients with favourable outcome among node-positive patients.
我们试图改进石蜡切片中E-钙黏蛋白免疫染色的评估方法,以区分导管浸润性乳腺癌侵袭性较低的亚型与其他亚型。
该方法对膜染色进行分级,并估计在各染色等级下癌组织染色面积的比例,得出免疫组化染色指数。在切点为0.35时,该指数将157例患者(P = 0.0188)和57例淋巴结阳性患者(P = 0.0006)分为两组,两组生存率不同。在多因素分析中(所有患者),E-钙黏蛋白免疫评分低于有丝分裂指数(SMI)(P = 0.0002),但仍具有显著性(P = 0.0031)。在淋巴结阳性患者中,E-钙黏蛋白的作用更强,优于仍具有显著性的SMI(P = 0.0023)(P = 0.0001),并且在Cox模型中,E-钙黏蛋白免疫染色与有丝分裂活性(SMI)相结合不需要其他预后指标的支持。
该研究表明,E-钙黏蛋白免疫染色可有效地用于在淋巴结阳性患者中找出预后良好的患者。